FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Oct 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5386968010 | A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera. | en | Definition | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| 5392900017 | A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythaemia vera. | en | Definition | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| 5143573017 | Ruxolitinib dependence (disorder) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5143574011 | Ruxolitinib dependence | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera. | Causative agent (attribute) | Ruxolitinib | true | Inferred relationship | Some | 1 | |
| A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera. | Is a | The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months. | false | Inferred relationship | Some | ||
| A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera. | Is a | Physiological dependence on substance in therapeutic use | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| A characteristic ruxolitinib discontinuation syndrome includes an acute relapse of disease symptoms, splenomegaly, and occasional hemodynamic decompensation. Symptoms can appear from less than 24 hours to up to 3 weeks after the abrupt discontinuation of ruxolitinib. | Due to | True | A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera. | Inferred relationship | Some | 2 |
| A characteristic ruxolitinib discontinuation syndrome includes an acute relapse of disease symptoms, splenomegaly, and occasional hemodynamic decompensation. Symptoms can appear from less than 24 hours to up to 3 weeks after the abrupt discontinuation of ruxolitinib. | After | True | A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera. | Inferred relationship | Some | 1 |
Reference Sets
Description inactivation indicator reference set